Principal Scientist
Mytos
Principal Scientist
Mytos
Automated scalable human cell manufacturing platform
You rarely get the chance to change an entire industry. But that's the position we find ourselves in. Join us, and you’ll help scale cures to patients that need them sooner.
We’ve developed fully-automated cell manufacturing sites powered by custom robotics - to scale therapies to millions of patients. Last year, patients were cured of diseases like Parkinson’s Disease and vision loss using stem-cell derived cells - but today these Regenerative Medicines are produced by hand, meaning they’re too expensive and hard to scale. With our automated CDMO, these therapies can now be scaled globally at low cost.
We've announced partnerships across multiple therapies so far ranging from Parkinson’s, to hearing loss, to bone repair - and raised $24m to expand into the market faster, and accelerate our development! Within the next 12-18 months, neurons grown on our machines will be going into Parkinson’s patient brains.
We’ve assembled a world-class team to take on this challenge, with ex-Dyson engineers and Nature-published scientists working hand-in-hand. You can learn more about your potential Mytos teammates here: Team
Mytos is backed by Y Combinator, the most successful startup program in the world which produced companies such as AirBnb, Dropbox, and Ginkgo Bioworks.
Required:
Desired:
Mytos.bio provides automated, end-to-end manufacturing for human cell types used in biotech. It sells and supports its proprietary Mytos Platform, which combines robotics and software to run cell culture processes without needing more staff. This turns traditional artisanal cell culture into scalable, repeatable production for large biotech firms working on cell therapies and drug development. The system works by integrating automated equipment and software workflows that manage culture, monitoring, and quality control, enabling consistent, high-quality cells at scale. Compared with competitors, Mytos.bio emphasizes a turnkey, scalable infrastructure that reduces headcount while delivering uniform results, backed by a team of hardware and software engineers and biologists, and recognition as a YCombinator alumnus and Forbes 30 Under 30. Its goal is to make large-scale cell production reliable and cost-effective so biopharma companies can accelerate therapies and drug development.
Explore more opportunities at Mytos